Ramucirumab plus erlotinib versus placebo plus erlotinib in previously untreated EGFR-mutated metastatic non-small-cell lung cancer (RELAY): exploratory analysis of next-generation sequencing results

BACKGROUND: Ramucirumab plus erlotinib (RAM + ERL) demonstrated superior progression-free survival (PFS) over placebo + ERL (PBO + ERL) in the phase III RELAY study of patients with epidermal growth factor receptor (EGFR)-mutated metastatic non-small-cell lung cancer (EGFR+ mNSCLC; NCT02411448). Nex...

Descripción completa

Detalles Bibliográficos
Autores principales: Garon, E.B., Reck, M., Nishio, K., Heymach, J.V., Nishio, M., Novello, S., Paz-Ares, L., Popat, S., Aix, S. Ponce, Graham, H., Butts, B.D., Visseren-Grul, C., Nakagawa, K.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2023
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10485403/
https://www.ncbi.nlm.nih.gov/pubmed/37390764
http://dx.doi.org/10.1016/j.esmoop.2023.101580

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10485403/
https://www.ncbi.nlm.nih.gov/pubmed/37390764
http://dx.doi.org/10.1016/j.esmoop.2023.101580

Ejemplares similares